Court Ruling on CMS Star Ratings for Clover Insurance: Implications & Analysis

A federal court ruling over Clover’s Medicare Advantage Star Rating has turned a technical methodology dispute into a much larger question for carriers, agencies, and the advisors who help clients understand plan stability.

On May 27, 2026, the U.S. District Court for the Southern District of Georgia ruled that the Centers for Medicare & Medicaid Services exceeded its authority in parts of the way it calculated Clover Insurance Company’s 2026 Medicare Advantage Star Rating. The court set aside Clover’s rating and ordered CMS to recalculate it in a manner consistent with the ruling.

That may sound like a carrier-level legal issue, but the practical ripple effects reach far beyond one plan. Star Ratings influence quality bonus payments, rebates, supplemental benefits, plan competitiveness, member perception, and the conversations agents have with Medicare beneficiaries during enrollment season.

Why This Ruling Matters

Medicare Advantage Star Ratings are more than a public-facing quality score. They help determine whether plans qualify for quality bonus payments, which can affect the resources available for benefits, pricing, service improvements, and market positioning. For many carriers, the difference between 3.5 stars and 4 stars is not cosmetic. It can change the economics of a contract.

Clover argued that its challenged rating cost the company approximately $120 million in quality bonus and related payments. The court’s order moved Clover’s recalculated rating from 3.5 stars to 4.5 stars, a result that immediately drew attention from other Medicare Advantage organizations, policy analysts, and legal teams watching similar disputes.

“CMS’s 2026 Star Rating for Clover is set aside, and Defendants are ordered to recalculate that rating in a manner consistent with this Order.”

U.S. District Court for the Southern District of Georgia

The Core Issue: Data, Authority, and Process

The Clover decision centered on two major legal questions. First, whether CMS used certain measures that went beyond the data Congress authorized for Star Ratings under the Medicare statute. Second, whether CMS should have used notice-and-comment rulemaking before relying on other measures in the rating calculation.

The court found that CMS improperly included certain measures and failed to follow required rulemaking procedures for others. That distinction is important. This was not simply a disagreement over whether CMS applied an approved formula correctly. It went deeper, into whether CMS had the authority and procedural foundation to use specific measures in the first place.

For carriers, that raises a bigger compliance question: when a rating system drives billions of dollars in payment consequences, how much transparency and formal rulemaking must exist behind each measure?

What Changed After the Decision

Following the ruling, CMS moved to recalculate certain Medicare Advantage Quality Bonus Payment ratings using narrower data parameters. The agency also indicated that contracts receiving a higher recalculated rating could have their ratings updated, while contracts that would calculate lower would not be downgraded through that process.

CMS also opened the door for affected Medicare Advantage organizations to submit information tied to the recalculation process and proposed a bid-related rerun for organizations whose revised ratings could affect payment year planning. At the same time, CMS preserved its ability to appeal the Clover ruling, meaning the legal questions are not necessarily settled.

“In light of a recent court decision, CMS is voluntarily recalculating the 2027 Quality Bonus Payment ratings for certain Medicare Advantage contracts.”

Centers for Medicare & Medicaid Services memo to Medicare Advantage organizations

Why Agents and Agencies Should Pay Attention

Agents do not calculate Star Ratings, but they often have to explain the real-world effects of those ratings. When ratings change, even because of litigation, beneficiaries may ask whether a plan is improving, declining, unstable, or being treated unfairly by regulators.

This is where agencies need a careful, compliant message. A court-ordered recalculation does not automatically mean a plan’s care quality changed overnight. It may mean the scoring method changed, the permissible data set changed, or the legal process behind the measure was challenged successfully.

Practical Talking Points for Medicare Teams

• Rating changes: explain that methodology changes can affect public scores.
• Client questions: focus on benefits, networks, drugs, doctors, and fit.
• Carrier updates: watch for revised ratings before enrollment materials finalize.
• Compliance risk: avoid overstating what a legal win means for quality.
• Renewal prep: build scripts for rating questions before AEP begins.

Carrier Implications Go Beyond Clover

The Clover ruling has already influenced other Star Ratings disputes. Humana referenced the case in its Fifth Circuit appeal, and other Medicare Advantage organizations have been watching closely to determine whether the same legal reasoning could apply to their own ratings.

For carriers, the issue is not only whether a recalculation produces a higher rating. It is whether Star Ratings litigation becomes a recurring part of Medicare Advantage financial planning. If more carriers challenge CMS methodology, the rating calendar, bid process, bonus assumptions, and benefit design timeline could all become more volatile.

That uncertainty matters because Star Ratings feed into strategic decisions long before consumers see plan options. A revised score can affect expected rebates, supplemental benefit flexibility, marketing posture, broker messaging, and the competitive strength of a plan in crowded counties.

A Bigger Debate Over Medicare Advantage Oversight

The Medicare Advantage program is already under intense scrutiny over payments, prior authorization, risk adjustment, supplemental benefits, marketing oversight, and member experience. Star Ratings sit at the center of that oversight framework because they are intended to measure quality and reward stronger performance.

The Clover decision does not eliminate the Star Ratings program. It does, however, put pressure on CMS to ensure that the measures used in the program are firmly grounded in statutory authority and adopted through proper procedures when required. For an industry built around annual deadlines, payment formulas, and highly regulated communications, process is not a technicality. It is the foundation for trust.

What to Watch Next

The next key question is whether CMS appeals and how broadly it applies the court’s reasoning beyond Clover. If CMS takes a narrow approach, more plans may pursue their own challenges. If CMS takes a broader approach, the agency may face operational and budget pressure from recalculated ratings and bonus payments.

Agencies should also monitor whether revised ratings affect carrier communications, certification materials, plan positioning, and enrollment-season talking points. Even if the average beneficiary never reads the court order, they may notice when a plan’s Star Rating, benefits, or messaging changes.

For insurance professionals, the takeaway is straightforward: Star Ratings are no longer just a quality indicator to glance at during plan comparisons. They are now a legal, financial, operational, and client communication issue that deserves a place in Medicare Advantage planning discussions.